Adverse outcome pathways: opportunities, limitations and open questions

Archives of Toxicology

Volumn 91, Issue 11, 2017, Pages 3477-3505

  Leist, Marcel ^a   Ghallab, Ahmed ^b,c   Graepel, Rabea ^d   Marchan, Rosemarie ^b   Hassan, Reham ^b,c   Bennekou, Susanne Hougaard ^e   Limonciel, Alice ^f   Vinken, Mathieu ^g   Schildknecht, Stefan ^a   Waldmann, Tanja ^a   Danen, Erik ^d   van Ravenzwaay, Ben ^h   Kamp, Hennicke ^h   Gardner, Iain ⁱ   Godoy, Patricio ^b   Bois, Frederic Y ^j   Braeuning, Albert ^k   Reif, Raymond ^b   Oesch, Franz ^l   Drasdo, Dirk ^m,n   Höhme, Stefan ^o   Schwarz, Michael ^p   Hartung, Thomas ^q   Braunbeck, Thomas ^r   Beltman, Joost ^d   Vrieling, Harry ^s   Sanz, Ferran ^t   Forsby, Anna ^u,ak   Gadaleta, Domenico ^v   Fisher, Ciarán ⁱ   Kelm, Jens ^w   Fluri, David ^w   Ecker, Gerhard ^x   Zdrazil, Barbara ^x   Terron, Andrea ^y   Jennings, Paul ^z   van der Burg, Bart ^aa   Dooley, Steven ^r   Meijer, Annemarie H ^ab   Willighagen, Egon ^ac,ad   Martens, Marvin ^ac   Evelo, Chris ^ac,ad   Mombelli, Enrico ^j   Taboureau, Olivier ^ae,af   Mantovani, Alberto ^ag   Hardy, Barry ^ah   Koch, Bjorn ^ab   Escher, Sylvia ^ai   van Thriel, Christoph ^b   Cadenas, Cristina ^b   Kroese, D ^aj   van de Water, Bob ^d   Hengstler, Jan G ^b   more..

^a UNIVERSITY OF KONSTANZ   (Germany)

^b TU DORTMUND UNIVERSITY   (Germany)

^c South Valley University   (Egypt)

^d LEIDEN UNIVERSITY   (Netherlands)

^e The Danish Environmental Protection Agency EPA   (Denmark)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^g VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^h BASF SE   (Germany)

ⁱ CERTARA UK LIMITED   (United Kingdom)

^j INSTITUT NATIONAL DE L ENVIRONNEMENT INDUSTRIEL ET DES RISQUES INERIS   (France)

^k FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

^l JOHANNES GUTENBERG UNIVERSITY   (Germany)

^m INRIA   (France)

ⁿ UNIVERSITÉ PIERRE ET MARIE CURIE   (France)

^o UNIVERSITY OF LEIPZIG   (Germany)

^p UNIVERSITY OF TÜBINGEN   (Germany)

^q JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^r UNIVERSITY OF HEIDELBERG   (Germany)

^s LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^t UNIVERSITAT POMPEU FABRA   (Spain)

^u KAROLINSKA INSTITUTE   (Sweden)

^v MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^w InSphero AG   (Switzerland)

^x UNIVERSITY OF VIENNA   (Austria)

^y EUROPEAN FOOD SAFETY AUTHORITY   (Italy)

^z AMSTERDAM INSTITUTE FOR MOLECULES   (Netherlands)

^aa BIODETECTION SYSTEMS B V   (Netherlands)

^ab LEIDEN UNIVERSITY   (Netherlands)

^ac MAASTRICHT UNIVERSITY   (Netherlands)

^ad Open PHACTS Foundation   (United Kingdom)

^ae INSERM   (France)

^af University of Copenhagen   (Denmark)

^ag ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^ah Douglas Connect GmbH   (Switzerland)

^ai FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^aj TNO   (Netherlands)

^ak STOCKHOLM UNIVERSITY   (Sweden)

more..

Author keywords

Binning of events; CCl4; Computational toxicology; Interspecies extrapolation; Liver fibrosis; Metabolism; Multi scale integration; Multiple hit events; Paracetamol; Pathway unidirectionality; Prioritization of compounds; Proof of non toxicity; Regulatory toxicology; Systems biology; Tumor promotion; Vinyl acetate

Indexed keywords

ADVERSE OUTCOME; ADVERSE OUTCOME PATHWAY; ARTICLE; ECOTOXICOLOGY; EPIDEMIOLOGICAL DATA; HUMAN; METABOLISM; NONHUMAN; PLASTICITY; PRIORITY JOURNAL; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TOXICITY ASSAY; TOXICOKINETICS; ANIMAL; C57BL MOUSE; HISTORY; PROCEDURES; QUALITY CONTROL; SYSTEMS BIOLOGY;

VINYL ACETATE; VINYL DERIVATIVE;

ADVERSE OUTCOME PATHWAYS; ANIMALS; ECOTOXICOLOGY; HISTORY, 21ST CENTURY; HUMANS; MICE, INBRED C57BL; QUALITY CONTROL; RISK ASSESSMENT; SYSTEMS BIOLOGY; TOXICOKINETICS; VINYL COMPOUNDS;

EID: 85031799653     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-017-2045-3     Document Type: Article

References (160)

1. Ames BN, Whitfield HJ Jr (1966) Frameshift mutagenesis in Salmonella. Cold Spring Harb Symp Quant Biol 31:221–225
2. Andersen ME, Krewski D (2009) Toxicity testing in the 21st century: bringing the vision to life. Toxicol Sci 107:324–330
3. Andersen ME, Krewski D (2010) The vision of toxicity testing in the 21st century: moving from discussion to action. Toxicol Sci 117:17–24
4. Ankley GT, Bennett RS, Erickson RJ et al (2010) Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem 29:730–741
5. Ball N, Cronin MTD, Shen J et al (2016) Toward good read-across practice (GRAP) guidance. ALTEX 33:149–166
6. Balmer NV, Leist M (2014) Epigenetics and transcriptomics to detect adverse drug effects in model systems of human development. Basic Clin Pharmacol Toxicol 115:59–68
7. Balmer NV, Weng M, Zimmer B et al (2012) Epigenetic changes and disturbed neural development in a human embryonic stem cell-based model relating to the fetal valproate syndrome. Hum Mol Genet 21:4104–4114
8. Balmer NV, Klima S, Rempel E et al (2014) From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol 88:1451–1468
9. Bal-Price A, Crofton K, Leist M et al (2015a) International STakeholder NETwork for developmental neurotoxicity (ISTNET): creating a developmental neurotoxicity (DNT) testing roadmap for regulatory purposes. Arch Toxicol 89:269–287
10. Bal-Price A, Crofton KM, Sachana M et al (2015b) Putative adverse outcome pathways relevant to neurotoxicity. Crit Rev Toxicol 45:83–91
11. Bal-Price A, Lein PJ, Keil KP et al (2017) Developing and applying the adverse outcome pathway concept for understanding and predicting neurotoxicity. Neurotoxicology 59:240–255
12. Basketter DA, Clewell H, Kimber I et al (2012) A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing—t4 report. ALTEX 29:3–91
13. Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Investig 15:209–218
14. Baumann J, Gassmann K, Masjosthusmann S et al (2016) Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events. Arch Toxicol 90:1415–1427
15. Becker RA, Ankley GT, Edwards SW et al (2015) Increasing scientific confidence in adverse outcome pathways: application of tailored Bradford-Hill considerations for evaluating weight of evidence. Regul Toxicol Pharmacol 72:514–537
16. Beliaeff B, Burgeot T (2002) Integrated biomarkers response: a useful tool for ecological risk assessment. Environ Toxicol Chem 21:1316–1322
17. Bhattacharya S (1948) A test for mutagenicity of methylcholanthrene. Nature 162:573
18. Blaauboer BJ, Boekelheide K, Clewell HJ et al (2012) The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans. Altex 29:411–425
19. Bois FY, Jamei M, Clewell HJ (2010) PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. Toxicology 278:256–267
20. Bolt HM, Foth H, Hengstler JG, Degen GH (2004) Carcinogenicity categorization of chemicals-new aspects to be considered in a European perspective. Toxicol Lett 151(1):29–41
21. Bouhifd M, Andersen ME, Baghdikian C et al (2015) The human toxome project. ALTEX 32:112–124
22. Casey WM (2016) Advances in the development and validation of test methods in the United States. Toxicol Res 32:9–14
23. Carbonell P, Lopez O, Amberg A, Pastor M, Sanz F (2017) Hepatotoxicity prediction by systems biology modeling of disturbed metabolic pathways using gene expression data. ALTEX 34(2):219-234
24. Clippinger AJ, Hill E, Curren R et al (2016) Bridging the gap between regulatory acceptance and industry use of non-animal methods. ALTEX 33:453–458
25. Crawford SE, Hartung T, Hollert H et al (2017) Green toxicology: a strategy for sustainable chemical and material development. Environ Sci Eur 29:16
26. Daneshian M, Kamp H, Hengstler J et al (2016) Highlight report: launch of a large integrated European in vitro toxicology project: EU-ToxRisk. Arch Toxicol 90:1021–1024
27. Daston G, Knight DJ, Schwarz M et al (2015) SEURAT: safety evaluation ultimately replacing animal testing—recommendations for future research in the field of predictive toxicology. Arch Toxicol 89:15–23
28. Delrue N, Sachana M, Sakuratani Y et al (2016) The adverse outcome pathway concept: a basis for developing regulatory decision-making tools. Altern Lab Anim 44:417–429
29. Depledge MH (1994) The rational basis for the use of biomarkers as ecotoxicological tools. In: Fossi MC, Leonzio C (ed.) Nondestructive biomarkers in vertebrates, pp. 271-295
30. Drasdo D, Hoehme S, Hengstler JG (2014) How predictive quantitative modelling of tissue organisation can inform liver disease pathogenesis. J Hepatol 61:951–956
31. Duffield JS, Forbes SJ, Constandinou CM et al (2005) Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 115:56–65
32. Edwards SW, Tan YM, Villeneuve DL et al (2016) Adverse outcome pathways-organizing toxicological information to improve decision making. J Pharmacol Exp Ther 356(1):170–181
33. Fasbender F, Widera A, Hengstler JG et al (2016) Natural killer cells and liver fibrosis. Front Immunol 7:19
34. Fehrenbacher N, Gyrd-Hansen M, Poulsen B et al (2004) Sensitization to the lysosomal cell death pathway upon immortalization and transformation. Cancer Res 64:5301–5310
35. Fischer FC et al (2017) Modeling exposure in the Tox21 in vitro bioassays. Chem Res Toxicol 30(5):1197–1208
36. Foghsgaard L, Wissing D, Mauch D et al (2001) Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. J Cell Biol 153:999–1010
37. Gantner F, Leist M, Küsters S et al (1996) T cell stimulus-induced crosstalk between lymphocytes and liver macrophages results in augmented cytokine release. Exp Cell Res 229:137–146
38. Gassmann K, Abel J, Bothe H et al (2010) Species-specific differential AhR expression protects human neural progenitor cells against developmental neurotoxicity of PAHs. Environ Health Perspect 118:1571–1577
39. Gerhardt E, Kügler S, Leist M et al (2001) Cascade of caspase activation in potassium-deprived cerebellar granule neurons: targets for treatment with peptide and protein inhibitors of apoptosis. Mol Cell Neurosci 17:717–731 (PubMed PMID: 11312607)
40. Ghallab A, Cellière G, Henkel SG et al (2016) Model-guided identification of a therapeutic strategy to reduce hyperammonemia in liver diseases. J Hepatol 64:860–871
41. Godoy P, Hewitt NJ, Albrecht U et al (2013) Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 87:1315–1530
42. Grinberg M, Stöber RM, Edlund K et al (2014) Toxicogenomics directory of chemically exposed human hepatocytes. Arch Toxicol 88(12):2261–2287
43. Guidance document on developing and assessing adverse outcome pathways (2017) Environment directorate joint meeting of the chemicals committee and the working party on chemicals, pesticides and biotechnology; Series on Testing and Assessment No. 184. http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2013)6&doclanguage=en. Accessed 4 Sept 2017
44. Hamon J, Jennings P, Bois FY (2014) Systems biology modeling of omics data: effect of cyclosporine a on the Nrf2 pathway in human renal cells. BMC Syst Biol 8:76
45. Hansson O, Castilho RF, Kaminski Schierle GS et al (2000) Additive effects of caspase inhibitor and lazaroid on the survival of transplanted rat and human embryonic dopamine neurons. Exp Neurol 164:102–111
46. Hansson O, Nylandsted J, Castilho RF et al (2003) Overexpression of heat shock protein 70 in R6/2 Huntington’s disease mice has only modest effects on disease progression. Brain Res 970:47–57
47. Hartung T (2009) Food for thought… on evidence-based toxicology. ALTEX 26:75–82
48. Hartung T (2013) Look back in anger—what clinical studies tell us about preclinical work. ALTEX 30:275–291
49. Hartung T (2016) Making big sense from big data in toxicology by read-across. ALTEX 33:83–93
50. Hartung T (2017) Utility of the adverse outcome pathway concept in drug development. Expert Opin Drug Metab Toxicol 13:1–3
51. Hartung T, McBride M (2011) Food for thought… on mapping the human toxome. ALTEX 28:83–93
52. Hartung T, van Vliet E, Jaworska J et al (2012) Systems toxicology. ALTEX 29:119–128
53. Hartung T, Luechtefeld T, Maertens A et al (2013a) Integrated testing strategies for safety assessments. ALTEX 30:3–18
54. Hartung T, Stephens M, Hoffmann S (2013b) Mechanistic validation. ALTEX 30:119–130
55. Hartung T, FitzGerald R, Paul J et al (2017) Systems toxicology—real world applications and opportunities. Chem Res Toxicol 30:870–882
56. Hengstler JG, Arand M, Herrero ME et al (1998) Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. Recent Results Cancer Res 154:47–85
57. Hengstler JG, Van der Burg B, Steinberg P et al (1999) Interspecies differences in cancer susceptibility and toxicity. Drug Metab Rev 31:917–970
58. Hengstler JG, Bogdanffy MS, Bolt HM et al (2003) Challenging dogma: thresholds for genotoxic carcinogens? The case of vinyl acetate. Annu Rev Pharmacol Toxicol 43:485–520
59. Hengstler JG, Marchan R, Leist M (2012) Highlight report: towards the replacement of in vivo repeated dose systemic toxicity testing. Arch Toxicol 86:13–15
60. Hirt U, Gantner F, Leist M (2000) Phagocytosis of non-apoptotic cells dying by caspase-independent mechanisms. J Immunol 164:6520–6529
61. Hoehme S, Hengstler JG, Brulport M et al (2007) Mathematical modelling of liver regeneration after intoxication with CCl(4). Chem Biol Interact 168:74–93
62. Hoehme S, Brulport M, Bauer A et al (2010) Prediction and validation of cell alignment along microvessels as order principle to restore tissue architecture in liver regeneration. Proc Natl Acad Sci USA 107:10371–10376
63. Hoffmann S, Hartung T (2006) Towards an evidence-based toxicology. Hum Exp Toxicol 25:497–513
64. Hoffmann S, de Vries RBM, Stephens ML et al (2017) A primer on systematic reviews in toxicology. Arch Toxicol 91(7):2551–2575
65. Horvat T, Landesmann B, Lostia A et al (2017) Adverse outcome pathway development from protein alkylation to liver fibrosis. Arch Toxicol 91:1523–1543
66. Huggett RJ, Kimerle RA, Mehrle PM, Bergman HL (1992) Biomarkers. Biochemical, physiological, and histological markers of anthropogenic stress. Lewis Publishers, Boca Raton, p 347
67. Jacobs MN, Colacci A, Louekari K et al (2016) International regulatory needs for development of an IATA for non-genotoxic carcinogenic chemical substances. ALTEX 33:359–392
68. Jalan R, Moreau R, Kamath PS, Arroyo V (2016) Acute-on-chronic liver failure: a distinct clinical condition. Semin Liver Dis 36(2):107–108
69. Jansen PL, Ghallab A, Vartak N et al (2017) The ascending pathophysiology of cholestatic liver disease. Hepatology 65(2):722–738
70. Jennings P (2013) Stress response pathways, toxicity pathways and adverse outcome pathways. Arch Toxicol 87:13–14
71. Jennings P, Limonciel A, Felice L et al (2013) An overview of transcriptional regulation in response to toxicological insult. Arch Toxicol 87:49–72
72. Kim KH, Chen CC, Monzon RI et al (2013) Matricellular protein CCN1 promotes regression of liver fibrosis through induction of cellular senescence in hepatic myofibroblasts. Mol Cell Biol 33:2078–2090
73. Kisseleva T, Cong M, Paik Y et al (2012) Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci USA 109:9448–9453
74. Kleensang A, Maertens A, Rosenberg M et al (2014) Pathways of toxicity. ALTEX 31:53–61
75. Kleinstreuer NC, Ceger PC, Allen DG et al (2016) A curated database of rodent uterotrophic bioactivity. Environ Health Perspect 124:556–562
76. Kleinstreuer NC, Ceger P, Watt ED et al (2017) Development and validation of a computational model for androgen receptor activity. Chem Res Toxicol 30:946–964
77. Knapen D, Vergauwen L, Villeneuve DL et al (2015) The potential of AOP networks for reproductive and developmental toxicity assay development. Reprod Toxicol 56:52–55
78. Krizhanovsky V, Yon M, Dickins RA et al (2008) Senescence of activated stellate cells limits liver fibrosis. Cell 134:657–667
79. Krug AK, Balmer NV, Matt F et al (2013a) Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants. Arch Toxicol 87:2215–2231
80. Krug AK, Kolde R, Gaspar JA et al (2013b) Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol 87:123–143
81. Krug AK, Gutbier S, Zhao L et al (2014) Transcriptional and metabolic adaptation of human neurons to the mitochondrial toxicant MPP(+). Cell Death Dis. 5:e1222
82. Kuegler PB, Zimmer B, Waldmann T et al (2010) Markers of murine embryonic and neural stem cells, neurons and astrocytes: reference points for developmental neurotoxicitiy testing—a review by the Transatlantic Think Tank for toxicology (t4). ALTEX 27:17–42
83. Latta M, Künstle G, Leist M et al (2000) Metabolic depletion of ATP by fructose inversely controls CD95- and tumor necrosis factor receptor 1-mediated hepatic apoptosis. J Exp Med 191:1975–1985
84. Leist M, Hartung T (2013) Inflammatory findings on species extrapolations: humans are definitely no 70-kg mice. Arch Toxicol 87:563–567
85. Leist M, Jäättelä M (2001) Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2:589–598
86. Leist M, Nicotera P (1997) Calcium and neuronal death. Rev Physiol Biochem Pharmacol 132:79–125
87. Leist M, Gantner F, Künstle G et al (1996) The 55-kD tumor necrosis factor receptor and CD95 independently signal murine hepatocyte apoptosis and subsequent liver failure. Mol Med 2:109–124
88. Leist M, Fava E, Montecucco C, Nicotera P (1997a) Peroxynitrite and nitric oxide donors induce neuronal apoptosis by eliciting autocrine excitotoxicity. Eur J Neurosci 9:1488–1498
89. Leist M, Gantner F, Naumann H et al (1997b) Tumor necrosis factor-induced apoptosis during the poisoning of mice with hepatotoxins. Gastroenterology 112:923–934
90. Leist M, Volbracht C, Kühnle S et al (1997c) Caspase-mediated apoptosis in neuronal excitotoxicity triggered by nitric oxide. Mol Med 3:750–764
91. Leist M, Gantner F, Künstle G et al (1998a) Cytokine-mediated hepatic apoptosis. Rev Physiol Biochem Pharmacol 133:109–155
92. Leist M, Volbracht C, Fava E et al (1998b) 1-Methyl-4-phenylpyridinium induces autocrine excitotoxicity, protease activation, and neuronal apoptosis. Mol Pharmacol 54:789–801
93. Leist M, Hartung T, Nicotera P (2008) The dawning of a new age of toxicology. ALTEX 25:103–114
94. Leist M, Efremova L, Karreman C (2010) Food for thought on considerations and guidelines for basic test method descriptions in toxicology. ALTEX 27:309–317
95. Leist M, Hasiwa N, Daneshian M et al (2012) Validation and quality control of replacement alternatives—current status and future challenges. Toxicol Res 1:8–22
96. Leist M, Hasiwa N, Rovida C et al (2014) Consensus report on the future of animal-free systemic toxicity testing. ALTEX 31:341–356
97. Lewin L (1885) Lehrbuch der Toxikologie: für Aerzte, Studierende und Apotheker (translation: textbook of Toxicology for physicians, students and pharmacists). Urban & Schwarzenberg, Wien
98. Lewin L (1924) Phantastica. Die betäubenden und erregenden Genussmittel. Für Ärzte und Nichtärzte (translation: Phantastica. Anaesthetic and stimulating drugs for physicians and laymen). Verlag von Georg Stilke, Berlin
99. Limonciel A, Aschauer L, Wilmes A et al (2011) Lactate is an ideal non-invasive marker for evaluating temporal alterations in cell stress and toxicity in repeat dose testing regimes. Toxicol In Vitro 25:1855–1862
100. Maertens A, Anastas N, Spencer PJ et al (2014) Green Toxicology. ALTEX 31:243–249
101. Matozzo V, Gagné F, Marin MG, Ricciardi F, Blaise C (2008) Vitellogenin as a biomarker of exposure to estrogenic compounds in aquatic invertebrates: a review. Environ Int 34:531–545
102. McCarty JF, Shugart LR (1990) Biomarkers of environmental contamination. Lewis Publishers, CRC Press, Boca Raton, p 457
103. Nicotera P, Leist M, Manzo L (1999) Neuronal cell death: a demise with different shapes. Trends Pharmacol Sci 20(2):46–51
104. NRC (2007) Toxicity testing in the 21st century: a vision and a strategy. The National Academies Press, Washington
105. NTP (2017) https://ntp.niehs.nih.gov/pubhealth/evalatm/test-method-evaluations/immunotoxicity/nonanimal/index.html. Accessed 4 Sept 2017
106. Nyffeler J, Karreman C, Leisner H et al (2017) Design of a high-throughput human neural crest cell migration assay to indicate potential developmental toxicants. ALTEX 34:7555–7594
107. Nylandsted J, Wick W, Hirt UA et al (2002) Eradication of glioblastoma, and breast and colon carcinoma xenografts by Hsp70 depletion. Cancer Res 62:7139–7142
108. Obiol-Pardo C, Gomis-Tena J, Sanz F, Saiz J, Pastor M (2011) A multiscale simulation system for the prediction of drug-induced cardiotoxicity. J Chem Inf Model 51:483–492
109. Ockleford C et al (2017) EFSA panel on plant protection products and their residues (PPR) investigation into experimental toxicological properties of plant protection products having a potential link to Parkinson’s disease and childhood leukaemia. EFSA J 15:4691
110. Oesch F, Herrero ME, Hengstler JG, Lohmann M, Arand M (2000) Metabolic detoxification: implications for thresholds. Toxicol Pathol 28(3):382–387
111. Oesch F, Herrero ME, Lohmann M, Hengstler JG, Arand M (2001) Sequestration of biological reactive intermediates by trapping as covalent enzyme-intermediate complex. Adv Exp Med Biol 500:577–586
112. Oki NO, Edwards SW (2016) An integrative data mining approach to identifying adverse outcome pathway signatures. Toxicology 28(350–352):49–61
113. Paparella M, Colacci A, Jacobs MN (2017) Uncertainties of testing methods: what do we (want to) know about carcinogenicity? ALTEX 34(2):235–252
114. Patlewicz G, Ball N, Becker RA et al (2014) Read-across approaches—misconceptions, promises and challenges ahead. ALTEX 31:387–396
115. Pelkonen O, Terron A, Hernandez AF et al (2017) Chemical exposure and infant leukaemia: development of an adverse outcome pathway (AOP) for aetiology and risk assessment research. Arch Toxicol 91(8):2763–2780
116. Polasek TM, Patel F, Jensen BP, Sorich MJ, Wiese MD, Doogue MP (2013) Predicted metabolic drug clearance with increasing adult age. Br J Clin Pharmacol 75(4):1019–1028
117. Poulin P, Theil FP (2002) Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 91:129–156
118. Radaeva S, Sun R, Jaruga B et al (2006) Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 130:435–452
119. Rahnenführer J, Leist M (2015) From smoking guns to footprints: mining for critical events of toxicity pathways in transcriptome data. Arch Toxicol 89:813–817
120. Ramachandran P, Iredale JP (2012) Macrophages: central regulators of hepatic fibrogenesis and fibrosis resolution. J Hepatol 56:1417–1419
121. Ramachandran P, Pellicoro A, Vernon MA et al (2012) Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc Natl Acad Sci USA 109:E3186–E3195
122. Rempel E, Hoelting L, Waldmann T et al (2015) A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol 89:1599–1618
123. Rostami-Hodjegan A (2012) Physiologically based pharmacokinetics joined with in vitro–in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther 92(1):50–61
124. Rovida C, Alépée N, Api AM et al (2015) Integrated testing strategies (ITS) for safety assessment. ALTEX 32:171–181
125. Samuel GO, Hoffmann S, Wright R et al (2016) Guidance on assessing the methodological and reporting quality of toxicologically relevant studies: a scoping review. Environ Int 92–93:630–646
126. Sauer JM, Hartung T, Leist M et al (2015) Systems toxicology: the future of risk assessment. Int J Toxicol 34:346–348
127. Schierle GS, Hansson O, Leist M et al (1999) Caspase inhibition reduces apoptosis and increases survival of nigral transplants. Nat Med 5:97–100
128. Schildknecht S, Pöltl D, Nagel DM et al (2009) Requirement of a dopaminergic neuronal phenotype for toxicity of low concentrations of 1-methyl-4-phenylpyridinium to human cells. Toxicol Appl Pharmacol 241:23–35
129. Schildknecht S, Pape R, Müller N et al (2011) Neuroprotection by minocycline caused by direct and specific scavenging of peroxynitrite. J Biol Chem 286:4991–5002
130. Schildknecht S, Karreman C, Pöltl D et al (2013) Generation of genetically-modified human differentiated cells for toxicological tests and the study of neurodegenerative diseases. ALTEX 30:427–444
131. Schildknecht S, Pape R, Meiser J et al (2015) Preferential extracellular generation of the active parkinsonian toxicant MPP+ by transporter-independent export of the intermediate MPDP+. Antioxid Redox Signal 23:1001–1016
132. Schildknecht S, Di Monte DA, Pape R et al (2017) Tipping points and endogenous determinants of nigrostriatal degeneration by MPTP. Trends Pharmacol Sci 38:541–555
133. Schliess F, Hoehme S, Henkel SG et al (2014) Integrated metabolic spatial-temporal model for the prediction of ammonia detoxification during liver damage and regeneration. Hepatology 60:2040–2051
134. Shinde V, Hoelting L, Perumal SS et al (2016) Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development—introduction of the STOP-Toxukn and STOP-Toxukk t. Arch Toxicol 91:839–864
135. Smirnova L, Hogberg HT, Leist M et al (2014) Developmental neurotoxicity—challenges in the 21st century and in vitro opportunities. ALTEX 31:129–156
136. Stephens ML, Betts K, Beck NB et al (2016) The emergence of systematic review in toxicology. Toxicol Sci 152:10–16
137. Stiegler N, Krug A, Matt F et al (2011) Assessment of chemical-induced impairment of human neurite outgrowth by multiparametric live cell imaging in high-density cultures. Toxicol Sci 121:73–87
138. Tacke F, Zimmermann HW (2014) Macrophage heterogeneity in liver injury and fibrosis. J Hepatol 60:1090–1096
139. Tian Z, Chen Y, Gao B (2013) Natural killer cells in liver disease. Hepatology 57:1654–1662. doi:10.1002/hep.26115
140. Tollefsen KE, Scholz S, Cronin MT et al (2014) Applying adverse outcome pathways (AOPs) to support integrated approaches to testing and assessment (IATA). Reg Toxicol Pharmacol 70:629–640
141. Trevan JW (1927) The error of determination of toxicity. Proc R Soc Lond B Biol Sci 101(712):483–514
142. Tsaioun K, Blaauboer BJ, Hartung T (2016) Evidence-based absorption, distribution, metabolism, excretion (ADME) and its interplay with alternative toxicity methods. ALTEX 33:343–358
143. Users’ handbook supplement to the guidance document for developing and assessing AOPs (2017) http://www.oecd-ilibrary.org/environment/users-handbook-supplement-to-the-guidance-document-for-developing-and-assessing-adverse-outcome-pathways_5jlv1m9d1g32-en. Accessed 4 Sept 2017
144. van der Burg B, Pieterse B, Buist H et al (2015a) A high throughput screening system for predicting chemically-induced reproductive organ deformities. Reprod Toxicol 55:95–103
145. van der Burg B, Wedebye EB, Dietrich DR et al (2015b) The ChemScreen project to design a pragmatic alternative approach to predict reproductive toxicity of chemicals. Reprod Toxicol 55:114–123
146. van Thriel C, Westerink R, Beste C et al (2011) Translating neurobehavioural endpoints of developmental neurotoxicity tests into in vitro assays and readouts. NeuroToxicol 33:911–924
147. Vartak N, Damle-Vartak A, Richter B et al (2016) Cholestasis-induced adaptive remodeling of interlobular bile ducts. Hepatology 63:951–964
148. Villeneuve DL, Crump D, Garcia-Reyero N, Hecker M, Hutchinson TH, LaLone CA, Landesmann B, Lettieri T, Munn S, Nepelska M, Ottinger MA, Vergauwen L, Whelan M (2014a) Adverse outcome pathway (AOP) development I: strategies and principles. Toxicol Sci 142:312–320
149. Villeneuve DL, Crump D, Garcia-Reyero N, Hecker M, Hutchinson TH, LaLone CA, Landesmann B, Lettieri T, Munn S, Nepelska M, Ottinger MA, Vergauwen L, Whelan M (2014b) Adverse outcome pathway development. II: best practices. Toxicol Sci 142:321–330
150. Vinken M (2015) Adverse outcome pathways and drug-induced liver injury testing. Chem Res Toxicol 28:1391–1397
151. Volbracht C, Leist M, Nicotera P (1999) ATP controls neuronal apoptosis triggered by microtubule breakdown or potassium deprivation. Mol Med. 5:477–489
152. Volbracht C, Fava E, Leist M et al (2001a) Calpain inhibitors prevent nitric oxide-triggered excitotoxic apoptosis. NeuroReport 12:3645–3648
153. Volbracht C, Leist M, Kolb SA et al (2001b) Apoptosis in caspase-inhibited neurons. Mol Med 7:36–48
154. Wilmes A, Limonciel A, Aschauer L et al (2013) Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. J Proteomics 79:180–194
155. Wilmes A, Bielow C, Ranninger C et al (2015) Mechanism of cisplatin proximal tubule toxicity revealed by integrating transcriptomics, proteomics, metabolomics and biokinetics. Toxicol In Vitro 30:117–127
156. Wittwehr C, Aladjov H, Ankley G et al (2017) How adverse outcome pathways can aid the development and use of computational prediction models for regulatory toxicology. Toxicol Sci 155:326–336
157. Wynn TA (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214:199–210
158. Zhu H, Bouhifd M, Kleinstreuer N et al (2016) Supporting read-across using biological data. ALTEX 33:167–182
159. Zimmer B, Lee G, Balmer NV et al (2012) Evaluation of developmental toxicants and signaling pathways in a functional test based on the migration of human neural crest cells. Environ Health Perspect 120:1116–1122
160. Zimmer B, Pallocca G, Dreser N et al (2014) Profiling of drugs and environmental chemicals for functional impairment of neural crest migration in a novel stem cell-based test battery. Arch Toxicol 88:1109–1126